ArticleInternational journal of genomics2026
m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma.Frontiers in genetics · 2026Article
- m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epigenetic medication, such as RNA 5-methylcytosine (m5C), is well-recognized as a key regulator in hepatic metabolism and immune responses. However, m5C regulatory mechanisms in NASH pathogenesis have not yet been clearly elucidated. Methods: By utilizing three bulk profiles of NASH patients acquired from GEO and integrative bioinformatic pipelines, such as Limma framework, consensus clustering, and machine learning, we first identified m5C-related molecular subgroups and hub genes for NASH patients. Besides, diagnostic performance and biological characteristics of m5C-related hub gene were estimated at bulk level. Indeed, the heterogeneity of m5C-related hub gene for NASH patients was deciphered in single-cell transcriptomic profiles at temporal and spatial manners, especially in artificial intelligence (AI)-driven virtual cells. Furthermore, potential therapeutic agents targeting m5C-associated hub genes for the treatment of NASH were enriched by AI-driven drug enrichment framework (DrugReflector) based on NASH bulk profile and then validated by molecular docking. Finally, in vitro studies quantified the expression of m5C-associated hub genes compared to normal control. Results: m5C can divide NASH patients into two various consensus groups with different molecular and immune patterns. Furthermore, ERCC2 and FOXC2 can be considered two upregulated m5C-associated hub genes involved in NASH pathogenesis, which were mainly distributed at cholangiocyte. BRD-K93672499 can be considered a multitarget therapeutic strategy targeting ERCC2 and FOXC2 for the treatment of NASH. Conclusion: Our study first deciphered the m5C in predictive and therapeutic potential for NASH patients, which gains more insight into their personalized and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.